Monday, June 24, 2013

Interview with Randoph Clower, PhD, JD

Below is a link to an interview in Metropolitan Corporate Counsel with Randolph Clower, PhD, JD, a biotech IP attorney in Buffalo, NY.
Why Buffalo?
Starting with a December 2012 announcement that New York State will spend $50 million to build a life-sciences innovation center on the Buffalo Niagara Medical Campus, the state aims to incubate a biotech cluster in Buffalo, fueled by University at Buffalo innovation, local medical expertise and private investment. 
In the interview Clower distinguishes between Big Pharma and Bio.
However, I would point to pages 65-67 of "Other Peoples Bodies" for a view of Pharma's penetration into the biotech sector.


  1. Hi Arthur,

    WNY/Buffalo has been my home for 30+ years, NYS is betting on a great group of entrepreneurs, businessmen and women, CEO’s, researchers, universities and the like. I applaud your intro.

    And, you are certainly correct with respect to the market/R&D penetration; the trends substantiate a coterminous progression to the balance. Distinguishing my comment, however, is misguided at least because a well-defined ‘bio’ or “biotech referent” remains unidentified from my point to yours. My comment concerns monies―practically―available to each sector, not whether the sectors, much less the monetary support, are mutually exclusive. If my spoken words were unclear, then hopefully this clears it up, to one end. See (reciting that “Lots of folks have been talking about the demise of Pharma R&D spending, especially with the recent cuts at Pfizer, GSK, and others. But the truth is far from that, as they still spend an enormous sum and dwarf the rest of the ecosystem.”); see also (reciting that “Biotech R&D is an important component of the discovery and development of new medicines. However, the perception that this sector is more successful than Big Pharma is incorrect. As shown by Gary Pisano in ‘Science Business – the Promise, the Reality and the Future of Biotech’ (Harvard Business School Press, 2006).”

    All the best,


  2. Dear Randy,
    Thank you for your contribution to the discourse.
    I think we are off on a side track here.
    The big question, as I see it, wrt AMP v Myriad is whether the bifurcation of eligibility into DNA and cDDNA claims will enhance or diminish biotech's and by extension mankind's respect for human life and its own humanity. It would be an extreme irony if biotech progress would lead us down a path to dehumanization.
    Best regards,